Advertisement

MDL 72,974 A a Novel MAO-B Inhibitor: A European Multicentre Trial in Parkinson’s Disease as an Adjunct to Levodopa

  • Thomas McIntyre
  • Damian Green
  • Gabrielle Cremer
  • Marion Merrell Dow
  • The European MDL 72,974 A Study Group
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

MDL 72,974 A, an irreversible inhibitor of monoamine oxidase type B (MAO-B),1 is currently in development for the treatment of Parkinson’s disease. This compound is highly specific and selective, with ED50 values for MAO-B and MAO-A of 0.18 and 8 mg/kg, acute treatment respectively, compared with 4.8 and 80 for L-deprenyl, the prototype MAO-B inhibitor.2 In addition, unlike L-Deprenyl, MDL 72,974 A is not metabolized in vivo to amphetamine or compounds having amphetamine-like effects,3 and has also been shown not to potentiate the effects of tyramine in healthy volunteers in doses up to 24 mg once per day.4

Keywords

Levodopa Dose Monoamine Oxidase Type EUROPEAN MULTICENTRE Trial Oral Tyramine England Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    M. Zreika, J.R. Fozard, M.W. Dudley, P. Bey, I.A. McDonald, and M.G. Palfreyman. MDL 72,974: a Potent and Selective Enzyme-Activated Irreversible Inhibitor of Monoamine Oxidase Type B with Potential for Use in Parkinson’s Disease, J. Neural. Transm. 243–254 (1989).Google Scholar
  2. 2.
    M.G. Palfreyman, I.A. MacDonald, M. Zreika, G. Cremer, K.D. Haegele, and P. Bey. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson’s Disease, J. Neural. Transm. 40: 101–111 (1993).Google Scholar
  3. 3.
    Moser P. The effects of L-deprenyl, MDL 72,974A and MDL 73,442A in rats trained to discriminate amphetamine from saline. Project report No. F-89–0112.Google Scholar
  4. 4.
    C. Hinze, M.K. Aschube, and J. Hardenberg. Pharmacodynamic of MDL 72,974A. Absence of effect on the pressure response to oral tyramine. Proceedings from the joint meeting of the 5th International Aminoxidase Workshop and 4th International Trace Amines Conferences (Galway), J. Neural. Transm. 41, in press, (1993).Google Scholar
  5. 5.
    W. Birkmayer, J. Knoll, P. Riederer, M.B.H. Youdim, V. Mars, and J. Marton. Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar Treatment in Parkinson’s Disease: A Long-Term Study, J. Neural. Transm. 64 (2): 113–127 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    U.K. Rinne. A New Approach to the Treatment of Parkinson’s Disease, Acta Neurol. Scand. (Suppl 95 ) 68: 7–144 (1983).Google Scholar
  7. 7.
    L.I. Golbe, A.N. Lieberman, M.D. Muenter, J.E. Ahlskog, G. Gopinathan, A.N. Neophytides, S.H.Foo, and R.C.Duvoisin. Deprenyl in the Treatment of Symptom Fluctuations in Advanced Parkinson’s Disease, Clin. Neuropharmacol. 11 (1): 45–55 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    P. Riederer, M.B.H. Youdim, W.D. Rausch, W. Birkmayer, K. Jellinger, D. Seeman. On the Mode of Action of L-Deprenyl in the Human Central Nervous System, J. Neural. Transm. 43: 217–226 (1978).PubMedCrossRefGoogle Scholar
  9. 9.
    J.Knoll. The Possible Mechanism of (-) Deprenyl in Parkinson’s Disease, J. Neural. Transm. 43: 177–198 (1978).Google Scholar
  10. 10.
    A.E. Lang, and S. Fahn. Assessment of Parkinson’s DisPace, in: “Quantification of Neurologic Deficit”, T.L. Munsat, ed, Boston, Butterworths: 285–309 (1989).Google Scholar
  11. 11.
    V. Myllyli, K. Sotaniemi, J. Aasly, O. Sjaastad, U. Rinne, T. McIntyre, and G. Cremer, An Open Multicentric Study of the Efficacy of MDL 72,974 A, a Monoamine Oxidase Type B (MAO-B) Inhibitor in Parkinson’s Disease. Advances in Neurology, Raven Press, Ltd. 60 (676–680) (1993).Google Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Thomas McIntyre
    • 1
  • Damian Green
    • 1
  • Gabrielle Cremer
    • 1
  • Marion Merrell Dow
    • 1
  • The European MDL 72,974 A Study Group
  1. 1.StrasbourgFrance

Personalised recommendations